Pandemic & Infectious Disease — 2026-06-09

Active Outbreak Tracker

Ebola Disease (Bundibugyo Virus) — Democratic Republic of Congo and Uganda

• Status: Public Health Emergency of International Concern; ongoing transmission in both countries
• Key Development: CDC released transmission model projections showing outbreak growth potential over three-month horizon. CDC data as of June 5 indicates very low acute respiratory illness-seeking behavior in the U.S., but African outbreak remains critical.
• Response: WHO convened expert advisory groups to assess candidate vaccines and therapeutics for Bundibugyo virus. WHO issued determination of PHEIC on May 17, 2026. CDC and Doctors Without Borders are mobilizing treatment capacity in affected regions.

2 sources

cdc.gov

Ebola Outbreak: Current Situation | Ebola | CDC

cdc.gov

cdc.gov

Respiratory Illness Activity — United States

• Status: Very low alert level for acute respiratory illness as of June 5, 2026
• Key Development: CDC surveillance shows minimal healthcare-seeking for respiratory illness. No specific pathogen dominance reported; routine respiratory season monitoring resuming Fall 2026.
• Response: CDC continues surveillance infrastructure; no emergency response required.

Vaccine & Treatment Pipeline

• WHO Immunization Agenda 2030 Mid-Point Commitment (WHO): At the Seventy-ninth World Health Assembly on June 9, 2026, WHO Director of Immunization reaffirmed global commitment to reaching "everyone, everywhere" with life-saving vaccines. This milestone marks the halfway point in the IA2030 strategic framework focused on equity and universal vaccine access.

• Obefazimod Phase 3 Success (Gossamer Bio): Positive topline results reported on June 8 from ABECT-1 and ABECT-2 trials for ulcerative colitis; obefazimod met primary endpoint for clinical remission at week 8 in the 50 mg dose cohort. Though not infectious disease-specific, demonstrates continued pipeline progress in immunological therapeutics.

• Eli Lilly Infectious Disease Expansion (Eli Lilly): On June 8, Eli Lilly announced three infectious disease acquisitions in a single day, signaling renewed corporate focus on ID therapeutics as a post-obesity growth strategy.

4 sources

who.int

who.int

cdn.who.int

cdn.who.int

who.int

who.int

cdn.who.int

cdn.who.int

Expert Analysis

Global health authorities converge on pandemic preparedness as a critical priority following the 2026 Ebola resurgence and COVID-19's ongoing legacy. The Lancet published commentary on June 26 highlighting that "the devastation caused by COVID-19 brought pandemic prevention, preparedness, and response (PPPR) to the forefront of the global political agenda," yet warns that global attention has waned amid competing crises. The upcoming UN High-Level Meeting on pandemic prevention, preparedness, and response is being framed as an opportunity to "elevate spillover prevention" and sustain political commitment.

Experts emphasize that surveillance and rapid outbreak response remain essential. The modeled scenario projections for the 2026 Ebola outbreak suggest the trajectory over the next few weeks will determine whether transmission escalates exponentially or stabilizes through intervention. Research priorities identified in The Lancet Global Health (May 2026) stress the need for improved epidemic intelligence systems, particularly in low- and middle-income countries, to enable faster detection and response.

Investment discussions center on closing the pandemic preparedness funding gap. Between 2022 and 2026, governments in the majority of low- and middle-income countries are projected to increase health spending equivalently by only 1% of GDP—below the levels recommended for robust PPPR capacity.

Global Health Security

WHO Convenes Expert Panels on Ebola Therapeutics and Vaccines (May 28, 2026): WHO assembled multiple expert and advisory groups to assess candidate treatments and vaccines for Bundibugyo virus in response to the DRC/Uganda outbreak. Recommendations are guiding emergency procurement and deployment decisions by national health ministries and GAVI.

UN Pandemic Preparedness Meeting Scheduled: Global policymakers are convening for the UN High-Level Meeting on pandemic prevention, preparedness, and response in late 2026. The meeting is expected to reaffirm commitments to the WHO Pandemic Accord and address implementation gaps in outbreak response and surveillance systems.

What to Watch Next

• Ebola outbreak case trajectory over next 2–3 weeks: Initial data from CDC transmission models will indicate whether current interventions slow or accelerate spread in DRC and Uganda. High case acceleration could signal need for expanded vaccine and therapeutics deployment.

• WHO vaccine and treatment recommendations (expected mid-June): Expert panels are finalizing assessments of Bundibugyo-specific candidate vaccines. Any recommendations for emergency use authorization will trigger regulatory fast-track reviews and global supply chain coordination.

• Eli Lilly infectious disease pipeline: The announced acquisitions signal market confidence in ID drug development; watch for Phase 2 and Phase 3 trial readouts from acquired companies that may accelerate availability of novel antimicrobial and antiparasitic agents.

Freshness Note: This article covers developments from June 2–9, 2026. All sources dated June 2 or later. Older Ebola outbreak coverage (May 17–May 29) has been excluded per editorial guidelines on preventing redundancy with prior week's reporting.